Justin Klee Sells 1,995 Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Justin Klee sold 1,995 shares of the stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $13.89, for a total transaction of $27,710.55. Following the sale, the chief executive officer owned 3,379,398 shares in the company, valued at $46,939,838.22. This represents a 0.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Amylyx Pharmaceuticals Stock Performance

Shares of AMLX opened at $16.92 on Thursday. Amylyx Pharmaceuticals, Inc. has a 52-week low of $2.60 and a 52-week high of $17.20. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -9.40 and a beta of -0.31. The business’s fifty day moving average is $13.26 and its 200-day moving average is $11.79.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. As a group, research analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Monday, December 29th. Citigroup raised their price objective on shares of Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the company a “buy” rating in a report on Friday, October 17th. HC Wainwright upped their price target on shares of Amylyx Pharmaceuticals from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Robert W. Baird boosted their price objective on shares of Amylyx Pharmaceuticals from $10.00 to $19.00 and gave the stock an “outperform” rating in a research note on Thursday, October 16th. Finally, Bank of America raised their target price on Amylyx Pharmaceuticals from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $17.25.

Trending Headlines about Amylyx Pharmaceuticals

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Neutral Sentiment: CEO Joshua B. Cohen sold a large block of 136,193 shares on Jan. 15 at an average price of $13.59 for roughly $1.85M, reducing his holding by about 3.87% though he still retains ~3.38M shares. This is a material insider disposition that may prompt short‑term pressure or raise questions about liquidity needs rather than company fundamentals. SEC filing: Joshua B. Cohen sale (136,193 shares)
• Neutral Sentiment: Two additional, much smaller insider sales occurred on Jan. 16: CEO Justin Klee sold 1,995 shares at an average ~$13.89, and CEO Joshua Cohen sold 1,974 shares at ~ $13.83 (each representing ~0.06% reductions in their holdings). These trades are routine in size relative to their total stakes and are less likely to change investor conviction on their own. Article: Justin Klee Sells 1,995 Shares Article: Joshua Cohen Sells 1,974 Shares InsiderTrades summary
• Negative Sentiment: The larger Jan. 15 CEO sale (136k shares) is the most significant item: while company fundamentals (recent EPS beat, analyst price targets) may support the stock, a six‑figure insider disposition of this size can be interpreted negatively by investors—it increases float available to the market and can trigger short‑term selling or re‑pricing risk if others interpret it as management de‑risking. SEC filing: Joshua B. Cohen sale (136,193 shares)

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Commodore Capital LP acquired a new stake in Amylyx Pharmaceuticals in the 3rd quarter valued at $55,386,000. First Light Asset Management LLC bought a new stake in shares of Amylyx Pharmaceuticals during the third quarter worth about $45,606,000. Adage Capital Partners GP L.L.C. increased its position in shares of Amylyx Pharmaceuticals by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock worth $56,408,000 after acquiring an additional 3,102,395 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Amylyx Pharmaceuticals by 418.6% in the 1st quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock worth $10,910,000 after acquiring an additional 2,487,617 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP acquired a new position in Amylyx Pharmaceuticals during the 3rd quarter valued at about $25,821,000. 95.84% of the stock is owned by institutional investors and hedge funds.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.